Navigation Links
TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business

Princeton, NJ (PRWEB) June 18, 2012

TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a leader in the Supply Chain Management and Life Sciences domains, concluded its annual two-day customer education and collaboration event, CONVERGE 2012, on June 5 at the JW Marriott Grande Lakes in Orlando, Florida. The keynote address was delivered by theoretical physicist, best-selling author and frequent contributor on networks such as the Discovery Channel, Dr. Michio Kaku. In its third year, CONVERGE 2012 attracted a strong cross-section of TAKE's customer base of small-to-medium and Fortune 500 companies that TAKE supports in the Life Sciences and Supply Chain domains. Continuing TAKE’s commitment to delivering expanded value to customers through highly topical content and access to industry experts, the speeches, customer presentations and panel discussions all focused on the theme of Business Transformation through Disruptive Technology.

Appropriately, Dr. Kaku opened the event with a look at technology 20 years into the future. He delighted the audience with a talk based on his two most recent books, Physics of the Future and Physics of the Impossible where he highlighted advancements in biotechnology and artificial intelligence, to include organ growing and internet glasses. Dr. John Underkoffler, Founder and Chief Scientist, Oblong Industries, and consultant on the film Minority Report, began the next day with an overview of how graphical user interfaces, such as those depicted in the movie, are emerging to make business data analysis and operations more efficient. Srinivasan HR, Vice Chairman and Vision Holder at TAKE Solutions elaborated on the company's vision and direction for the remainder of 2012 and into 2014.

Analysts from IDC Health Insights and ChainLink Research discussed the four pillars of disruptive technology—mobility, cloud, big data, social media—and how they are impacting the entire life science value chain, including global supply chain management for manufacturers and distributors. In addition to multiple customer presentations and panel discussions related to disruptive technologies in a number of industries ranging from oil and gas, consumer packaged goods, aerospace and defense and high tech, attendees also enjoyed one-on-one and group product demonstrations of TAKE’s OneSCM®, Gemini Series®, PharmaReady™ and SafetyReady™ products as well as an overview of TAKE’s product and services roadmaps for the next eighteen months.

"The life science industry is actively undergoing transformational change and companies best able to embrace disruptive technologies will be in a prime position to succeed. With its clear forward focus, TAKE Solutions is well positioned to help its clients to translate emerging disruptive strategies into action,” said Dr. Alan Louie, research director, IDC Health Insights.

“It is rare to get a chance to dialogue, get inspired as well as get practical insights on how to leverage technology to transform our businesses and our lives. Converge was a very unique and powerful event to do just that!” said Ann Grackin, CEO of Chainlink Research. “TAKE’s leadership in creating a collaborative platform with rich applications that cover the key businesses interactions between trading partners like Demand and Procurement Collaboration as well as Inventory not only assist the critical business processes, but also provide visibility across the supply chain.“

“It has been a delight to bring together leading experts and our customers for this event. CONVERGE 2012 was a great opportunity to discuss and share best practices both with industry experts as well as innovators from other Industries," said Ram Yeleswarapu, President & CEO, TAKE Solutions. “We look forward in the coming years to continuing discussions on issues and challenges that are common within and across industries. Our goal is for CONVERGE to emerge as a forum for our customers and their industries to voice their views across a common platform.”

Learn more about TAKE Solutions’ here.

About TAKE Solutions
TAKE Solutions is an international business technology company with products backed by a strong domain expertise in Life Sciences and Supply Chain Management. With extensive technology expertise in Business Intelligence and Business Process Management, TAKE´s track record in delivering world-class solutions throughout global markets is well proven. Technological innovations have always been the driving force of the company, which in turn helps TAKE´s customers achieve consistent growth in business.

Headquartered in Chennai, TAKE drives its Global Delivery Centre from India and Middle East. The Company has a strong presence in the USA with the Life Sciences Domain Excellence center located in Princeton, New Jersey and Supply Chain Domain Excellence center located in Austin, Texas. The Company conducts business today with more than 400 customers worldwide.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
2. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
3. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
4. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
5. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
6. BioLife Solutions 2011 Revenue Up 33%
7. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
8. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
9. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
10. A mouse model brings new perspectives on Lafora disease
11. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
Post Your Comments:
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):